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Abstract:  The  determination  of  clopidogrel,  an  antiplatelet  agent,  was  per-
formed at a gold electrode in pH 3.7 acetate buffer using cyclic voltammetry 
(CV) and square wave voltammetry (SWV). Each voltammogram was charac-
terized by the well defined peak at approximately 1.0 V. The current of anodic 
stripping peak exhibited a linear dependence on the clopidogrel concentration 
in the range from 317.89 to 935.16 μg cm-3. The obtained linearity was applied 
to determine clopidogrel in the tablet form of the pharmaceutical preparation 
(Plavix®). The results were compared to the UV spectrophotometric and HPLC 
methods. 
Keywords: cyclic voltammetry; acetate buffer; tablet; UV, HPLC. 
INTRODUCTION 
Clopidogrel  (CLP),  methyl  (+)-(S)-α-(o-chlorophenyl)-6,7-dihydrothieno-
[3,2-c]pyridine-5(4H)-acetate (Fig. 1), is an antiplatelet agent widely used in the 
prevention of ischemic stroke, myocardial infarction and stroke.1,2  
It inhibits platelet aggregation by selectively preventing the binding of ade-
nosine diphosphate (ADP) to its platelet receptor.3 This drug reduces thrombotic 
events in a wide range of patients (e.g., recent myocardial infarction, established 
peripheral arterial disease and acute coronary syndrome). Clopidogrel is an inac-
tive prodrug, and a biotransformation by the liver is necessary to induce expres-
sion of its anti-aggregating activity.4 It is rapidly absorbed and undergoes exten-
sive metabolism after oral administration and its plasma concentration goes down 
considerably rapidly.5 
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  Fig. 1. Structure of clopidogrel. 
Analytical methods for the determination of clopidogrel include mostly chro-
matographic and spectrophotometric techniques: gas chromatography–mass spec-
trometry (GC–MS),6 liquid chromatography–mass spectrometry (LC–MS),7–10 
high-performance  liquid  chromatography  (HPLC),11–13  liquid  chromatogra-
phy,14 LC–MS/MS,15 LC–ESI-MS/MS,16 thin-layer chromatography (TLC),17 
high-performance  thin-layer  chromatography  (HPTLC),18  UV  spectrophoto-
metry.19–24 Furthermore, the determination of clopidogrel and its impurities by 
capillary electrophoresis was reported.25 
Electrochemical determination of clopidogrel in standard form and pharma-
ceutical  preparations  using  the  differential  pulse  voltammetry  (DPV)  method 
with a  glassy  carbon  working  electrode  was  recently  published.26  Hitherto, a 
detailed voltammetric determination and electrochemical behaviour of clopido-
grel at a gold electrode have not been published.  
The aim of this study was to investigate the electrochemical behaviour of 
clopidogrel  using  cyclic  voltammetry  and  to  present  its  quantitative  determi-
nation at a gold electrode in pH 3.7 acetate buffer using square wave voltam-
metry. Clopidogrel was studied as the pure standard or in the pharmaceutical 
preparation (Plavix®). The square wave voltammetry (SWV) method was applied 
to determine the amount of clopidogrel in the tablet form of a pharmaceutical 
preparation (Plavix®) and the results were compared with the UV spectrophoto-
metric and HPLC methods. 
EXPERIMENTAL 
Materials 
Clopidogrel bisulphate (CLB) standard was kindly provided by Hemofarm AD, Vršac, 
Serbia.  Plavix®  tablets  containing  a  75  mg  dose  of  clopidogrel  were  obtained  from  local 
pharmacies.  HPLC  grade  acetonitrile,  methanol,  ammonium  acetate,  sodium  bicarbonate, 
sulphuric  acid,  sucrose,  dichloromethane,  sodium  dihydrogenphosphate  (NaH2PO4H2O), 
H3PO4 and NaHCO3 (p.a. purity), were obtained from Merck. Diethylamine, analytical grade, 
and ammonium hydroxide 25 % were obtained from J. T. Baker. All solutions were prepared 
with  water  obtained  from  a  Millipore  system  (18  M  cm).  Acetate  buffer  was  prepared 
according to the USP pharmacopoeial procedure. 
Cyclic voltammetry 
The three electrode electrochemical cell used for the cyclic voltammetry measurements 
was described in detail previously.27,28 The cyclic voltammetry measurements were performed 
using an Autolab potentiostat/galvanostat Pgstat128N (Metrohm Autolab B.V., The Nether-
lands). 
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Polycrystalline gold served as the working electrode, a gold wire was used as the counter 
electrode and a saturated calomel electrode as the reference electrode. Polycrystalline gold 
(Pine rotating disc, used as the stationary electrode, surface area 0.500 cm2) was polished with 
diamond paste, cleaned with a mixture of water (18 M cm) and sulphuric acid and further 
cleaned with deionised water (18 M cm) in an ultrasonic bath. All the potentials are given 
vs. SCE. Prior to the addition of the investigated substance, the electrolyte was deoxygenated 
by  purging  with  nitrogen.  All  the  experiments  were  performed  at  room  temperature.  The 
voltammetric examinations of all the substances used were performed in acetate buffer solu-
tion. The potential was cycled between 0 and 1.5 V at a sweep rate of 50 mV s-1.  
Square wave voltammetry 
Square wave voltammetry (SWV) measurements were also performed using the Autolab 
potentiostat/galvanostat. The operating parameters were: step size 2 mV, pulse size 20 mV, 
frequency 8 Hz and scan rate 15 mV s-1.  
Solution preparation for voltammetry 
Working standard solutions were prepared daily by dissolving appropriate amounts of 
CLB in 10 cm3 of methanol and diluting to 100 cm3 with acetate buffer (pH 3.7).  
Preparation of the standard solutions for the analysis of clopidogrel bisulphate as a content of 
a solid dosage form 
Twenty Plavix® tablets were weighed and then the average mass per tablet was deter-
mined. The tablets were grounded to a fine powder in a mortar. The required amount of the 
crushed tablets powder was dissolved in 50 cm3 of methanol. After sonication for 10 min, the 
mixture was filtered into a 100 cm3 volumetric flask. The residue was washed three times with 
acetate buffer (pH 3.7) and the volume was completed to the mark with the same buffer and 
stored in dark bottle at 4 °C. The obtained concentrations were checked by HPLC. 
UV spectrophotometric instrument 
The spectrophotometric analysis were performed on an Agilent 8453 UV–Vis spectro-
photometer with a photodiode array (PDA) detector for measurement of the complete ultra-
violet to visible light spectrum. The UV–Vis spectra were recorded in a quartz cuvette of 1 cm 
path length. The spectrophotometer was connected to a computer with Agilent ChemStation 
software that was used for all the spectrophotometric measurements and data processing. The 
samples were tested using  a  UV–Vis analytical procedure  analogous to  the procedure for 
content uniformity determination given in the US pharmacopeia monograph for clopidogrel 
tablets (USP 36 NF 31).29 
Preparation of standard stock solution for spectrophotometric analysis 
About 100 mg of clopidogrel bisulphate standard was accurately weighed, transferred to 
a 50 ml volumetric flask and dissolved in methanol. The flask was shaken and volume was 
made up to the mark with methanol.  
Linearity for clopidogrel bisulphate for spectrophotometric analysis 
Appropriate aliquots of standard stock solutions were taken in different volumetric flasks 
and diluted to obtain final concentrations of 0.04, 0.06, 0.08, 0.1, 0.2, 0.4 and 1.0 mg cm-3 of 
clopidogrel bisulphate in Britton Robinson buffer, pH 3.7. The UV spectra of the solutions 
were recorded and the determination of clopidogrel was realized employing the absorption at 
270 nm, the wavelength of maximum absorption.  
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High performance liquid chromatography (HPLC) – instrumentation and chromatographic 
conditions 
An Agilent HPLC system equipped with 1100 series high pressure binary gradient pump 
along with pulse damper, a photodiode array detector with an auto liquid sampler handling 
system was used for the analysis of the samples. The samples were tested using an HPLC 
analytical procedure analogous to the analytical procedure given in a US pharmacopeia mono-
graph for the assay of clopidogrel tablets and determination of related substances (USP 36 NF 
31).29 The HPLC system was equipped with a 4.6 mm × 15 cm analytical column Ultron ES-
OVM immobilized with ovomucoid as chiral stationary phase  of 5 µm particle size (USP 
packing designation L57). The column eluent was monitored at a detection wavelength 220 
nm. The mobile phase consisted of filtered and degassed mixture of phosphate buffer and 
HPLC grade acetonitrile in 75:25 ratio. Phosphate buffer was prepared by dissolving 1.36 g of 
monobasic potassium  phosphate  in  1000  cm3  of  purified  water.  The  chromatography  was 
performed at room temperature at a flow rate of 1.0 cm3 min-1. Data was recorded using 
OpenLab CDS, Ezchrom edition, software. 
Preparation of standard stock solution for HPLC analysis 
About 100 mg of clopidogrel bisulphate standard was weighed accurately and transferred 
to a 100 cm3 volumetric flask and dissolved in methanol. The flask was shaken and volume 
was made up to the mark with methanol.  
HPLC linearity for clopidogrel bisulphate 
Appropriate aliquots of standard stock solutions were taken in different volumetric flasks 
and diluted to obtain final concentrations of 0.04, 0.2, 0.4, 0.6, 0.8, 1.0 and 1.2 mg cm-3 of 
clopidogrel bisulphate in Britton Robinson buffer, pH 3.7. Equal volumes of 10 µl of the 
solutions were injected and chromatograms were recorded.  
HPLC analysis of clopidogrel bisulphate as a content of a solid dosage form 
Twenty tablets of Plavix were weighed and thoroughly powdered. The average of one 
tablet was weighed, transferred into a 100 cm3 volumetric flask, 50 cm3 of methanol was 
added and sonicated for 5 min and stirred for 30 min. The solution was diluted with methanol 
to volume, and mixed. 5 cm3 of this solution was transferred to a flask and diluted with Brit-
ton–Robinson buffer, pH 3.7, to 50 cm3. A portion of this solution was passed through a 0.45-μm 
pore size PTFE membrane filter and discatograms were recorded. The pharmaceutical formul-
ation was analyzed by performing six independent determinations. 
RESULTS AND DISCUSSION 
Electrochemical determination of clopidogrel in standard form and in phar-
maceutical  preparations  by  differential  pulse  voltammetry  on  a  glassy  carbon 
electrode was recently successfully performed26 and pH 3.7 acetate buffer in 
mixture with methanol was found to be the optimal electrolyte. The intention was 
to study the feasibility of the electrochemical determination of clopidogrel as a 
pure standard and as the content of commercial tablets Plavix® by square wave 
voltammetry on a gold electrode only in pH 3.7 acetate buffer as electrolyte. 
The electrochemical behaviour of the pure standard of clopidogrel on gold 
electrode was first studied by cyclic voltammetry in pH 3.7 acetate buffer. As is 
presented in Fig. 2, clopidogrel exhibited an apparent oxidative ability in this 
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electrolyte on a gold electrode. The cyclic voltammogram shows the beginning of 
anodic activity of clopidogrel in double layer region from 0.2 to 0.6 V. An appa-
rent anodic current maximum appears at 1.0 V before oxide formation on the 
gold electrode and second one at 1.17 V in the area of oxide formation. The rapid 
increase of anodic current on gold oxide at 1.30 V in the presence of clopidogrel 
was observed as well as its shift by 0.1 V to a more negative potential, compared 
to a clean gold electrode (dashed line in Fig. 2). 
 
Fig. 2. Cyclic voltammogram of an Au electrode in pH 3.7 acetate buffer, dashed line, and 
after the addition of clopidogrel (concentration 32.0 μg cm-3 ), full line; sweep rate: 50 mV s-1. 
Only the first sweep is presented. 
This voltammetric behaviour indicated the possible successful quantitative 
determination of clopidogrel using square wave voltammetry. 
The application of square wave voltammetry for the quantitative determi-
nation of clopidogrel on the gold electrode is presented in Fig. 3. The SW vol-
tammograms for different concentrations of clopidogrel were recorded in pH 3.7 
acetate buffer in the potential range from 0 to 1.5 V at a scan rate of 15 mV s–1. 
Before each scan, the compound was accumulated at the electrode surface at 0 V 
for 180 s. Under these conditions, the oxidation of clopidogrel proceeded before 
oxide formation on Au and reached maximum currents at the onset potential of 
Au oxide formation. Each voltammogram was characterized by a well defined 
peak at approximately 1.0 V. The currents of anodic stripping peak exhibited a 
linear dependence on the clopidogrel concentration, as shown in the inset of Fig. 3. 
As already mentioned, the successful electrochemical determination of clopi-
dogrel in standard form and pharmaceutical preparations described in literature26 
was performed by differential pulse voltammetry on a glassy carbon electrode in 
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a mixture of pH 3.7 acetate buffer and methanol. In the present study, square 
wave anodic stripping voltammetry was used to determine clopidogrel at a gold 
electrode in a similar mixture of acetate buffer (pH 3.7) with methanol in a 50:50  
(V/V) ratio. However, the results obtained showed inhibition of the gold electrode 
surface by methanol, resulting in more than two-times smaller anodic currents of 
clopidogrel oxidation, as presented in Fig. 4. This indicates that further analysis 
of clopidogrel in Plavix ® should be continued in acetate buffer (pH 3.7) alone. 
 
Fig. 3. Square wave anodic stripping voltammograms of clopidogrel at a gold electrode in 
acetate buffer (pH 3.7). Clopidogrel concentration: a) 317.89, b) 474.49, c) 622.03, d) 775.63 
and e) 935.16 μg cm-3. Accumulation time: 180 s at E = 0.0 V; step size 2 mV, pulse size 20 
mV, frequency 8 Hz, scan rate 15 mV s-1. Inset: The linear dependency of the anodic peak 
current vs. concentration of clopidogrel. 
 
Fig.  4.  Square  wave  anodic 
stripping  voltammograms  of 
935.16 μg cm-3 clopidogrel at a 
gold electrode in acetate buffer, 
pH 3.7 (full line), and in acetate 
buffer  (pH  3.7)/methanol,  1:1, 
V/V  (dashed  line),  solutions. 
Accumulation  time:  180  s  at 
E  =  0.0  V;  step  size  2  mV, 
pulse size 20 mV, frequency 8 
Hz, scan rate 15 mV s-1. 
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The  voltammetric  behaviour  of  clopidogrel as the content  of  commercial 
tablets Plavix® was also in a first stage investigated by cyclic voltammetry. Its 
voltammetric behaviour even in the presence of the excipients present in Plavix® 
showed the same anodic activity as the standard substance, presented in Fig. 2, 
with a negligible reduction in the values of the current maximums.  
Similarly as for clopidogrel, the oxidation of Plavix® at a gold electrode 
using square wave voltammetry proceeded at potentials before the formation of 
oxide on the Au. The square wave voltammogram was characterized by a well 
defined peak at approximately 1.0 V.  
The obtained linear relationship between current and concentration of clopi-
dogrel in acetate buffer (pH 3.7) by SW voltammetry within the concentration 
range 0.317–0.935 mg cm–3 (Table I) was used for the determination of clopi-
dogrel in tablet form (Plavix®) and the results were compared with those obtained 
by the UV and HPLC methods. The validation of the SW procedure was carried 
out by evaluation of the limit of detection (LOD), limit of quantification (LOQ) 
and recovery. The LOD and LOQ were calculated from the calibration curves as 
kSD/b where k = 3 for LOD and 10 for LOQ, SD is the standard deviation of the 
intercept and b is the slope of the calibration curve.30,31 The LOD and LOQ 
values for the SW voltammetry method were 117.50 and 391.66 μg cm–3, respec-
tively. 
TABLE I. Determination of CLP by SW voltammetry (SWV), UV spectrophotometry and 
HPLC 
Parameter  SWV  UV  HPLC 
Range / mg cm-3  0.317–0.935  0.030–0.747  0.032–0.962 
Regression equationa 
Slope   0.00012  1.81  23358783.00 
SD of slope  7.09×10-6  0.0003  0.0026 
Intercept  0.1457  0.0076  36117.71 
SD of intercept  0.0047  0.0001  0.0015 
Regression coefficient  0.9947  0.9999  0.9999 
Recovery, %  99.6  99.94  99.57 
SD / %  1.11  1.65  1.38 
LOD / μg cm-3  117.50  8.56  8.24 
LOQ / μg cm-3  391.66  30.46  29.28 
aY = a + bc, where c is the concentration of clopidogrel, mg cm
-3; Y is the current per area unit, mA cm
-2, absor-
bance, A, and peak area unit, mAu, for the SWV, UV and HPLC methods, respectively, and SD is the standard 
deviation 
Recovery studies were also performed to judge the accuracy of the SW vol-
tammetry method by performing six measurements at low, intermediate and high 
CLP  concentrations  (317.89,  622.03  and  935.16  μg  cm–3).  Mean  percentage 
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recoveries of 99.6 % with relative standard deviation of 1.11 % were found and 
are presented in Table I. 
Tablet solutions of appropriate concentrations were prepared and voltammo-
grams were taken under the same experimental conditions (Fig. 5). The obtained 
results show that the excipients in the tablet were not electro-active and did not 
affect the voltammetric analysis. The results of drug analysis by the SW voltam-
metric technique are compared in Table II with those obtained by the UV-spec-
trophotometric and high pressure liquid chromatography methods. The analytical 
results demonstrated that the amount of active substance in the Plavix® tablet 
was within the limits specified in the pharmacopoeia. This indicates that the pro-
posed method could be an alternative to chromatographic and spectrophotometric 
methods. 
 
Fig.  5.  Square  wave  anodic 
stripping  voltammograms  of 
clopidogrel  standard  (full  line) 
and  clopidogrel  as  the  content 
of  commercial  tablets  Plavix® 
(dashed line) at a gold electrode 
in acetate buffer (pH 3.7). Clo-
pidogrel  concentration:  474.49 
μg  cm-3.  Accumulation  time: 
180 s at E = 0.0 V; step size 2 
mV,  pulse  size  20  mV,  frequ-
ency 8 Hz, scan rate 15 mV s-1. 
TABLE II. Comparative studies for the determination of clopidogrel in Plavix
® tablets (75 mg 
per tablet) 
Parameter 
  Method   
SWV  UV  HPLC 
Mean coontenta, mg  74.6  76.1  75.2 
SD / %  0.8  1.1  0.3 
aEach value is the mean of six experiments 
The results obtained in this work show that the SW voltammetry method 
exhibited an accuracy that recommends it for routine and quality control analysis 
of the drug in pharmaceutical dosage forms. 
CONCLUSIONS 
The electrochemical determination of clopidogrel, as standard and in com-
mercial tablets, Plavix®, was performed at a gold electrode in pH 3.7 acetate buf-
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fer using square wave voltammetry. Prior to the determination, their electroche-
mical behaviour was studied by cyclic voltammetry. It was shown by both tech-
niques that each voltammogram is characterized by a well defined peak at appro-
ximately 1.0 V. The linear dependence of currents of the anodic stripping peak 
on clopidogrel concentration was used to determine the amount of clopidogrel in 
Plavix® tablets. The results demonstrated that the SW voltammetric technique 
could be used directly, easily and rapidly for the determination of clopidogrel in 
tablet dosage forms. The SW voltammetric technique was compared to the results 
of drug analysis by UV and HPLC methods. The analytical results demonstrated 
that the amount of active substance in the Plavix® tablets was within the limits 
specified in the pharmacopoeia. This indicates that the proposed method could be 
an alternative to chromatographic and spectrophotometric methods.  
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Клопидогрел је антитромботски агенс из тијенопиридинске класе, који се користи 
за инхибирање формирања крвних угрушака при лечењу коронарне артеријске болести, 
периферне васкуларне болести, и цереброваскуларне болести. Електрохемијско пона-
шање клопидогрел стандарда и као састојка таблете Plavix® је дефинисано цикличном 
волтаметријом. Њихово квантитативно одређивање на електроди од злата у ацетатном 
пуферу, pH 3,7, урађено је волтаметријом са правоугаоним импулсима (SWV). Показано 
је обема техникама да је сваки волтамограм окарактерисан добро дефинисаним струј-
ним врхом на 1,0 V. На основу линеарне зависности анодних струја од концентрације 
клопидогрел  стандарда  одређена  је  маса  клопидогрела  у  Plavix®  таблети.  Добијени 
резултати показују да SWV техника може бити коришћена директно, брзо и једноставно 
за  одређивање  клопидогрела  у  таблетама.  Резултати  добијени  SWV  волтаметријском 
техником су поређени са резултатима анализе клопидогрела UV спектрофотометријом 
и течном хроматографијом са високим перформансама. Аналитички резултати показују 
да је маса активне супстанце у таблетама Plavix® у оквиру лимита спецификованог фар-
макопејом. То указује да волтаметрија са правоугаоним импулсима може бити успешна 
алтернатива хроматографским и спектрофотометријским методама. 
(Примљено 13. септембра 2013) 
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